Brought to you by 
Merck licenses Portola's betrixaban; returns rights
19 Apr 2021
Executive Summary
Portola Pharmaceuticals (cardiovascular diseases, inflammatory conditions, and cancer) has granted Merck exclusive worldwide development and commercialization rights to its Phase II anticoagulant betrixaban.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com